Genertec Universal Medical Group Co (2666.HK) Stock Price

Genertec Universal Medical Group Co Ltd operates primarily in the healthcare and medical industry. With a focus on providing comprehensive medical services, the company offers a wide range of healthcare solutions including hospital management, medical equipment manufacturing, pharmaceutical research and development, and healthcare technology services. Genertec Universal Medical Group Co Ltd strives to contribute to the advancement of healthcare by delivering innovative and high-quality services to patients.

The main competitors of Genertec Universal Medical Group Co Ltd in the market include Beijing Tiantan Hospital, China National Pharmaceutical Group Corporation, and China Resources (Holdings) Co Ltd.

Genertec Universal Medical Group Co Ltd is a diversified healthcare company based in China. Established in 2001, the company has since grown to become one of the leading providers of medical products and services in the country. With a strong focus on innovation and quality, Genertec Universal Medical Group has continuously expanded its product portfolio and developed strategic partnerships with global medical technology companies. The company's commitment to improving healthcare standards in China has earned it a solid reputation within the industry. With a comprehensive range of medical devices, pharmaceuticals, and healthcare solutions, Genertec Universal Medical Group continues to contribute to the advancement of healthcare in China and beyond.

Some significant milestones achieved by Genertec Universal Medical Group Co Ltd include successful partnerships with leading healthcare organizations, expansion into international markets, and the development of innovative medical technologies. The company has established strategic alliances with renowned medical institutions, enhancing its research and development capabilities. Genertec Universal Medical Group Co Ltd has also experienced positive growth in global markets, reflecting its commitment to delivering high-quality medical products and services worldwide. Additionally, the company has introduced groundbreaking advancements in medical technology, improving patient care and revolutionizing the healthcare industry.

Genertec Universal Medical Group Co Ltd is primarily present in China.

Genertec Universal Medical Group Co Ltd embraces a set of core values and corporate philosophy that defines its operations. As a leading medical services company, Genertec Universal Medical Group Co Ltd prioritizes excellence, patient-centered care, and innovation in the healthcare industry. With a focus on providing high-quality medical services, the company upholds integrity, professionalism, and compassion in all its endeavors. By combining cutting-edge technology and advanced medical expertise, Genertec Universal Medical Group Co Ltd aims to enhance patient outcomes and contribute to the overall advancement of healthcare.

Analysts currently set an average price target of 6.97 CNY for the Genertec Universal Medical Group Co stock (median: 6.97 CNY), implying +80.3 % versus the latest price. The consensus is based on 8 analyst ratings.

Genertec Universal Medical Group Co Analyst Price Targets 2026

8 analysts currently rate the Genertec Universal Medical Group Co stock: 7 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Genertec Universal Medical Group Co to generate revenue of 15.10 B CNY and earnings per share of 1.13 CNY.

Genertec Universal Medical Group Co Analyst Price Targets 2026

Converted at the current exchange rate, the Genertec Universal Medical Group Co share trades at 0.52 EUR (3.86 CNY).

The Genertec Universal Medical Group Co share (2666.HK) is listed on 3 stock exchanges, including: Hongkong (HKEX) (2666.HK), Frankfurt (5UM.F).

The company Genertec Universal Medical Group Co Ltd (GUMG) is an internationally operating company in the healthcare sector. It was founded in 2001 as a subsidiary of Genertec Holding Co Ltd, one of the leading Chinese energy companies. GUMG's business model is to offer comprehensive healthcare services that encompass all aspects of the healthcare industry. The company consists of various divisions, all contributing to the overall strategy of the healthcare company in different ways. One of GUMG's most important divisions is the hospital group. The company operates multiple hospitals in China and strives to provide high-quality medical services at the highest level. The hospitals offer specialized treatments for cancer patients, cardiovascular diseases, as well as neurology and orthopedics. Another important area of GUMG is research and development. The company has been investing in the research of new drugs and treatment methods for years, collaborating closely with renowned universities and research institutions in China. GUMG has already achieved several significant medical breakthroughs and continues its research activities to further improve healthcare in the future. In addition to hospitals and research, GUMG also heavily invests in the development of medical devices and technologies. The company operates its own research and development team that develops innovative products and brings them to the international market. Some of the products offered by GUMG include ultrasound devices, endoscopy equipment, EKG systems, and other medical instruments. Lastly, GUMG is also heavily involved in the training of medical professionals. The company operates its own training facilities and advocates for the improvement of medical education in China and other countries. GUMG aims to educate a new generation of physicians who are equipped to meet the challenges of modern healthcare. In summary, GUMG's business model is focused on providing comprehensive healthcare services. The company operates hospitals, conducts research and develops new medical products and technologies, and engages in the training of medical professionals. GUMG collaborates closely with universities and research institutions and strives to improve healthcare worldwide.

The expected revenue of Genertec Universal Medical Group Co is 15.10 B CNY. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Genertec Universal Medical Group Co is 2.30 B CNY. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Genertec Universal Medical Group Co is currently 3.41. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Genertec Universal Medical Group Co stock.

The price-to-sales ratio (P/S) of Genertec Universal Medical Group Co is currently 0.52. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Genertec Universal Medical Group Co stock.

The Eulerpool Quality Score for Genertec Universal Medical Group Co is 5/10.

The ISIN of Genertec Universal Medical Group Co is HK0000255361. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Genertec Universal Medical Group Co is A14V3L. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Genertec Universal Medical Group Co is 2666.HK. The ticker symbol is used to trade Genertec Universal Medical Group Co shares on the stock exchange.